OpenAI has acquired Orchestra Bio, a platform founded by Indian American tech entrepreneur Ashoka Rajendra to help biopharma teams coordinate the complex process of drug development.
“We’re bringing Orchestra’s team and technology together with Rosalind, our AI models and tools for life sciences research,” open AI announced Tuesday aiming “to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner.”
Rajendra “started Orchestra Bio four years ago to help biotech and pharma teams advance their drug development programs,”
he posted on X. “Today, we’re thrilled to share that Orchestra Bio is joining OpenAI to continue our mission at an even greater scale.”
Read: Indian American cardiovascular genetics innovator wins 2026 Population Research Prize (October 2, 2026)
Terms of the deal were not disclosed, but the startup had reportedly raised around $20 million as of 2025 from backers like Andreessen Horowitz, Atria, and 8VC.
“Developing medicines is incredibly complex, spanning thousands of decisions and dependencies across discovery, preclinical, manufacturing, and clinical,” Rajendra wrote. “AI has now reached an inflection point where people and agents can take this on together. Agents can handle planning, orchestration, and analysis, while scientists and program leaders focus on the decisions that require their expertise.”
OpenAI said it’s adding Orchestra’s team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.
Read: Indian American founded Aiseptor joins Cornell Tech’s Runway Startup program (September 24, 2026)
OpenAI says it has already won some big names as customers for Rosalind, including, it says, Moderna and Novo Nordisk.
Rosalind brings its AI models and tools to life sciences researchers. GPT‑Rosalind helps scientists reason through questions in biology and chemistry, Open AI stated. Rosalind Workbench connects those capabilities with scientific tools and data to help researchers analyze results and plan experiments.
Orchestra brings a team with experience across biotech, software, and AI, along with a platform built to coordinate drug development.
“Together, we aim to build agents that help teams connect scientific findings with the studies, decisions, and next steps needed to advance a potential medicine,” the company stated.